Mapping Transporter-Mediated DDI Pathways

Why Transporter Location and Direction Matter

A transporter-mediated drug-drug interaction (DDI) cannot be interpreted from a transporter name alone. The key questions are which membrane the transporter occupies, which way it moves the victim drug, and what happens to the drug after that movement. The same kind of inhibition can increase or decrease plasma exposure depending on whether it blocks entry into an organ, exit from a cell, or movement toward elimination.

This tutorial maps major intestinal, hepatic, and renal pathways. It focuses on mechanistic direction and likely consequences, not on selecting transporter evidence or calculating clinical inhibition inputs. The examples use hypothetical pathway fractions to make the reasoning explicit; they are not predictions for a particular drug.

A useful starting point is to label compartments before considering an interaction. For each transporter, record the membrane, the source compartment, the destination compartment, and the downstream fate of the drug. Inhibition then means reduced transport through that particular route; it does not automatically mean reduced total absorption or clearance.

Mapping the Intestinal Pathways

After an oral dose, a victim drug may move from the gut lumen into an enterocyte, cross the enterocyte into portal blood, or return from the enterocyte to the lumen. These directions have different consequences. Apical efflux transporters such as P-glycoprotein (P-gp) and BCRP can move substrate from the enterocyte back into the lumen. Inhibiting that route can increase the fraction reaching portal blood, provided that the drug can cross the remaining barriers and that other loss processes do not compensate.

Transporters at the apical membrane can also facilitate uptake from the lumen into the enterocyte. Inhibiting such an uptake route can reduce entry into the cell and potentially reduce absorption. Thus, “intestinal transporter inhibition” has no single direction of effect. The membrane orientation and transport direction must be specified.

For orally administered drugs, gut transport can alter the amount reaching the portal circulation and, in turn, systemic availability. It may also change the timing or rate of absorption, so a change in peak concentration need not be proportional to a change in total exposure. A simple fraction-of-dose calculation is useful for pathway mapping, but it does not represent all absorption kinetics.

Mapping Hepatic Uptake and Efflux

The liver presents several distinct transport steps. Basolateral uptake transporters, including OATP1B1 and OATP1B3, move drug from blood into hepatocytes. Once in the hepatocyte, the drug may be metabolized, transported into bile, or returned to blood. Canalicular efflux transporters such as P-gp, BCRP, and MRP2 move drug from hepatocytes toward bile. Basolateral efflux transporters, including MRP3 and MRP4, can move substrates from hepatocytes back toward blood.

Inhibiting hepatic uptake can reduce hepatocyte entry. If uptake supplies drug to hepatic metabolism or biliary excretion, this may reduce those routes of elimination and raise plasma exposure. At the same time, it can lower drug exposure inside the liver. The plasma and hepatic concentration changes can therefore point in opposite directions.

Inhibiting canalicular efflux can reduce biliary transport. This may increase hepatocyte retention, but the plasma consequence depends on what happens next: the drug may leave by another route, return to blood, or undergo more intracellular metabolism. A transporter’s role in one clearance route does not establish the net effect on whole-body clearance without considering competing routes.

Mapping Renal Uptake and Efflux

Renal secretion across proximal tubular cells commonly involves sequential transport steps. Basolateral uptake from blood into the tubular cell can be mediated by OAT1 or OAT3 for some organic anions, or OCT2 for some organic cations. Apical efflux then moves drug from the cell into tubular fluid; MATE1 and MATE2-K are examples of apical transporters involved in secretion of some organic cations. The overall direction is blood to cell to urine.

If either step is inhibited, active secretion may decrease. Inhibiting basolateral uptake restricts entry into the tubular cell; inhibiting apical efflux can restrict exit into urine and may increase intracellular drug. Reduced secretion can lower renal clearance and raise plasma exposure when renal secretion is an important elimination route. It can also reduce urinary delivery, while intracellular accumulation may have separate consequences.

Filtration is a separate route: it moves unbound drug from plasma into the nephron and does not require these active transport steps. Reabsorption can also return drug from tubular fluid to blood. Therefore, a transporter interaction should be interpreted as a change to one component of renal handling, not as a direct measure of total renal clearance.

A Compact Justification for the Exposure Direction

For linear pharmacokinetics after an intravenous dose, total exposure over the dosing interval is proportional to dose divided by total clearance. This follows from the definition of clearance as dose rate divided by concentration: over a complete observation interval, dose divided by AUC is clearance. Consequently, reducing a clearance component while holding dose and other components fixed raises AUC.

For oral dosing, the corresponding relationship includes systemic availability \(F\): \(\mathrm{AUC}=F\times\mathrm{Dose}/CL_{\mathrm{total}}\). Thus an intestinal or hepatic interaction that changes \(F\) can alter oral AUC independently of clearance. The simple examples above either specify that \(F\) is unchanged or calculate a change in delivery as a proxy under stated assumptions. They should not be combined without accounting for both availability and clearance.

Compare Pathways Before Predicting a Net Effect

A pathway map helps distinguish transporter effects from other mechanisms. An enzyme interaction changes a metabolic process; a transporter interaction changes movement between compartments. Both can affect clearance or availability, and both may occur together. A change in blood concentration alone may not reveal which process changed. Likewise, comparing whole-organ clearance estimates without membrane direction can conceal whether the affected step was uptake, intracellular metabolism, or efflux.

The table gives directional expectations, not universal outcomes. The dominant pathway may differ between drugs, and multiple transporters can handle the same substrate. Moreover, if an uptake transporter and an efflux transporter act in opposing directions, inhibiting both can produce competing effects. A net prediction requires the relevant pathways and their relative contributions.

Assumptions, Diagnostics, and Common Pitfalls

A pathway-based interpretation is strongest when the victim drug is transported by the specified transporter, the inhibitor reaches the relevant membrane, and the interaction does not simultaneously change unrelated clearance or availability processes. The fraction-based examples further assume linear pharmacokinetics, unchanged competing routes, and the specific proportional reductions stated in each example. These are teaching assumptions, not facts that can be presumed in a real prediction.

• Check the direction. “Uptake inhibition” is incomplete unless the source and destination compartments are named.
• Check the organ fate. Reduced hepatic uptake may lower liver entry and hepatic elimination at once; those implications are not contradictory.
• Keep parallel routes in the balance. Filtration, other transporters, metabolism, and nonrenal clearance can limit the effect of blocking one route.
• Separate oral availability from systemic clearance. An intestinal interaction may change \(F\), while a hepatic or renal interaction may change clearance; either can affect AUC.
• Compare more than one observation when diagnosing a mismatch. A plasma AUC change alone may be consistent with several mechanisms. Time course, urinary or biliary recovery, and tissue-specific evidence can help distinguish them.

A common mistake is to reason, “an efflux transporter is inhibited, so plasma concentration must rise.” That conclusion ignores the destination. Inhibiting intestinal efflux back to the lumen may increase absorption, but inhibiting efflux from a hepatocyte into bile may increase intracellular retention, with a plasma effect that depends on return-to-blood and alternative elimination routes. The correction is to trace the full route and then identify which measured exposure or clearance component that route controls.